Matching geography
Reports matching your search in:
 
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
Region: All Regions > Middle East
Category: All Categories > Life Sciences > Pharmaceuticals > Diseases & Conditions > Insomnia & Sleep Disorders
(5 reports matching your criteria)
 
Calming and Sleeping in the United Arab Emirates
2/4/2013 | published by: Euromonitor International
... and Librax are widely available under-the-counter from chemists/pharmacies. As the country’s economic situation improved in 2011, many consumers traded up from OTC to Rx products, viewing the latter as offering greater efficacy. Euromonitor International's Calming ...  |  read more...
$900.00
Calming and Sleeping in Saudi Arabia
11/12/2012 | published by: Euromonitor International
... to customers. However, there was growing concern regarding the misuse of Rx calming and sleeping during the review period, with the government being concerned about the health impact of this trend. Consequently, the government increasingly ...  |  read more...
$900.00
Calming and Sleeping - Israel
6/29/2010 | published by: Euromonitor International
... political and security state. Drugstores and pharmacies all over Israel reported dramatic sales increases of these products, mainly during the first two quarters of 2009, as this period was characterised by the unstable economic and ...  |  read more...
$900.00
Calming and Sleeping - Iran
5/6/2010 | published by: Euromonitor International
... The most popular product in this category is Alprazolam. Euromonitor International's Calming and Sleeping Products in Iran report offers a comprehensive guide to the size and shape of the market at a national level. It ...  |  read more...
$900.00
Calming and Sleeping - United Arab Emirates
4/30/2010 | published by: Euromonitor International
... to opt for prescription medication, believing this to be more effective than over the counter alternatives. Growth in this category though registered at a current value of 4% compared to a review period value CAGR ...  |  read more...
$900.00